¿¬¼ö°­ÁÂ
¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (2ÀÏÂ÷) : 2024-04-26

¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (2ÀÏÂ÷) : 2024-04-26
±³À°ÀÏÀÚ : 2024-04-26
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ ¼­¿ï (ÁöÇÏ2Ãþ, ÁöÇÏ1Ãþ, 1Ãþ, 4Ãþ)

±³À°ÁÖÁ¦ : ¼¼°èÀ¯¹æ¾ÏÇмú´ëȸ 2024 ¹× Çѱ¹À¯¹æ¾ÏÇмú´ëȸ (GBCC 2024) (2ÀÏÂ÷)

ÁÖÃÖ±â°ü : Çѱ¹À¯¹æ¾ÏÇÐȸ
´ã´çÀÚ : À̽ÿÂ
¿¬¶ôó : 02-3452-7291  

À̸ÞÀÏ : gbcc@intercom.co.kr

±³À°Á¾·ù : ¿Ü°ú, ¼ºÇü¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, ¸¶ÃëÅëÁõÀÇÇаú, ÀÇ»çÇÐ, ¿¹¹æÀÇÇÐ, ÀÇÇб³À°, ÀÇ·á°æ¿µ

Âü¼®¿¹»óÀÎ : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 30 ½Ã°£ 27ºÐ

¼¼ºÎ¼ö°­·á : 800,000¿ø  

ºñ°í [Á¶±âµî·Ï(2023.11.01-2024.02.01)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 400,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 500,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 150,000[»çÀüµî·Ï(2024.02.02-2024.04.05)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 480,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 600,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 200,000[ÇöÀåµî·Ï(2024.04.25-2024.04.27)]Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSȸ¿ø) 640,000Àü¹®ÀÇ/±³¼ö/ȸ»ç(KBCSºñȸ¿ø) 800,000Àü°øÀÇ/°£È£»ç/¿¬±¸¿ø/±ºÀÇ°ü/Çлý 250,000*http://gbcc.kr/Contents.asp?LoadPage=Instruction&Tap=B


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 08:00~08:45 [Satellite Symposium 2: Novartis] Ribociclib, Pushing the Boundary of CDK4/6 Inhibitor Soo Jung Lee(Kyungpook National Univ. Chilgok Hospital, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 08:45~09:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 09:00~09:25 [Junior Doctors Forum] Experiences with Successfully Organizing and Operating Education Programs Yazan Masannat(Broomfield Hospital, Mid & South Essex NHS Trust, United Kingdom)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 09:25~09:50 [Junior Doctors Forum] Fifteen-Year Journey of ASTRRA Trial Woochul Noh(Konkuk Univ. Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 09:00~09:25 [Symposium 4: Immunotherapy Going Beyond the Current Limits] Tailoring Post-Neoadjuvant Treatment in TNBC-Current Treatment and Future Perspectives Sung Hoon Sim(National Cancer Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 09:25~09:50 [Symposium 4: Immunotherapy Going Beyond the Current Limits] Overcoming Resistance of Immunotherapy in TNBC - Mechanism and Novel Treatment Soo-Chin Lee(National Univ. Cancer Institute, Singapore (NCIS), Singapore)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 09:50~10:15 [Symposium 4: Immunotherapy Going Beyond the Current Limits] Expanding Immunotherapy Beyond TNBC - New Strategy in HER2 and ER Positive Breast Cancer Jee Hyun Kim(Seoul National Univ. Bundang Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 09:00~09:20 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Addressing Sexual Health Disturbance During Endocrine Therapy: Unique Challenges Among Various Age Groups Tara Sanft(Yale School of Medicine, U.S.A.)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 09:20~09:40 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Current Therapeutic Options for Fertility Preservation: Challenges Ahead Matteo Lambertini(Univ. of Genova - IRCCS Policlinico San Martino Hospital , Italy)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 09:40~10:00 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Leveraging Bone Health Issue in Women Receiving Endocrine Therapy: Practical Applications and Future Perspectives So-Youn Jung(National Cancer Center, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 10:00~10:15 [Panel Discussion 5: Confronting Unique Deterioration Caused by Estrogen Deprivation Therapy] Discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 09:00~09:25 [Symposium 5: Local Tumor Control in Metastatic Breast Cancer] Role of SBRT in Oligometastasis and Oligoprogression Jee Suk Chang(Yonsei Cancer Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 09:25~09:50 [Symposium 5: Local Tumor Control in Metastatic Breast Cancer] Toilet RT in Symptomatic Advanced Breast Cancer Haeyoung Kim(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 09:50~10:15 [Symposium 5: Local Tumor Control in Metastatic Breast Cancer] Optimal RT Approach for Intracranial Metastasis Yutaro Koide(Aichi Cancer Center Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 09:00~09:25 [Nursing Session 1: Present and Future of Breast Cancer Specialist Nurse] The Experience of Breast Cancer Practice Nurses Insook Lee(Changwon National Univ., Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 09:25~09:50 [Nursing Session 1: Present and Future of Breast Cancer Specialist Nurse] Present and Future of Specialist Breast Cancer Care Nurses Jayoung Ahn(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 09:50~10:15 [Nursing Session 1: Present and Future of Breast Cancer Specialist Nurse] Best Practice of Advanced Nurse Practitioner in Breast Cancer Patient Care Byong Hee Jeon(Yonsei Univ. Health System, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:00~09:08 [Oral Presentation 5] VITAMIN D SUPPLEMENTATION HAS A POSITIVE EFFECT ON PATHOLOGIC COMPLETE RESPONSE: A PROSPECTIVE RANDOMISED STUDY Enver Ozkurt(Istanbul Demiroglu Bilim University, Republic of Turkiye)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:08~09:16 [Oral Presentation 5] RFA FOR EARLY BREAST CANCER, WHICH HAS RECENTLY BECOME COVERED BY MEDICAL INSURANCE IN JAPAN Masato Takahashi(Hokkaido University Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:16~09:24 [Oral Presentation 5] ASSESSING THE CUMULATIVE INCIDENCE OF CARDIAC EVENTS AND MAJOR ADVERSE CARDIAC EVENTS IN BREAST CANCER PATIENTS AFTER RADIATION THERAPY Tae Hyun Kim(Seoul National Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:24~09:32 [Oral Presentation 5] RELATIONSHIP OF IMMEDIATE BREAST RECONSTRUCTION AND THE DEVELOPMENT OF LYMPHEDEMA IN BREAST CANCER PATIENTS WITH RADIOTHERAPY Soon Woo Hong(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:32~09:40 [Oral Presentation 5] COMPARISON OF POST-RADIOTHERAPY SIDE EFFECTS BETWEEN MODERATELY HYPOFRACTIONATED AND ULTRA-HYPOFRACTIONATED WHOLE-BREAST IRRADIATION FOR BREAST CANCER: AN ANALYSIS OF A PROSPECTIVE COHORT STUDY Tae Hoon Lee(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:40~09:48 [Oral Presentation 5] ASSOCIATION BETWEEN GENOMIC FEATURES AND RADIATION RESPONSE IN METASTATIC BREAST CANCER PATIENTS UNDERGOING PALLIATIVE RADIOTHERAPY Hyeonseok Choi(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:48~09:56 [Oral Presentation 5] BREAST OUTCOMES OF REPEAT LUMPECTOMY IN PATIENTS WITH IPSILATERAL BREAST TUMOR RECURRENCE (IBTR) WITH OR WITHOUT RADIOTHERAPY: A COMPREHENSIVE ANALYSIS Eunju Shin(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 09:56~10:04 [Oral Presentation 5] EFFICACY AND SAFETY OF RESPIRATORY MOTION MANAGEMENT USING CONTINUOUS POSITIVE AIRWAY PRESSURE IN RADIOTHERAPY FOR BREAST CANCER : A PROSPECTIVE TRIAL Jung Bin Park(Seoul National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 10:04~10:12 [Oral Presentation 5] CLINICOPATHOLOGICAL CHARACTERISTICS AND PROGNOSTIC IMPLICATIONS OF SUBTYPES IN DUCTAL CARCINOMA IN SITU: A RETROSPECTIVE ANALYSIS" Soo Youn Bae(The Catholic Univ. of Korea, Seoul St. Mary)

Åä·Ð 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 10:05~10:55 [Junior Doctors Debate] Can We Omit Radiation Therapy for Stage I, Luminal-Type Breast Cancer Undergoing a Breast-Conserving Surgery? Han-Byoel Lee(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 10:55~11:45 [Junior Doctors Debate] Should Contralateral Risk-Reducing Mastectomy Be Offered for All Breast Cancer Patients with a Pathologic BRCA Mutation? Tristen Park(Yale School of Medicine, U.S.A.)

ÈÞ½Ä 04¿ù 26ÀÏ 10:15~10:30 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 10:30~10:55 [Symposium 6: Tumor Heterogeneity and Dynamics in Breast Cancer: Unveiling Insights through Tissue and Liquid Biopsies] Therapy Induced Tumor Evolution Represents a Novel Therapeutic Target Gordon Mills(Oregon Health Sciences, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 10:55~11:20 [Symposium 6: Tumor Heterogeneity and Dynamics in Breast Cancer: Unveiling Insights through Tissue and Liquid Biopsies] Spatial and Temporal Dynamics in the Tumor Microenvironment through Immunotherapy Christina Curtis(Stanford Univ., U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 11:20~11:45 [Symposium 6: Tumor Heterogeneity and Dynamics in Breast Cancer: Unveiling Insights through Tissue and Liquid Biopsies] Serial Circulating Tumor DNA Landscape Portraying Clonal Evolution Pedram Razavi(Memorial Sloan Kettering Cancer Center, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 10:30~10:50 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Overview on the Treatment Diversity for Breast Cancer Worldwide (WHO) Benjamin Anderson(Univ. of Washington, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 10:50~11:05 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Asian Data on the Treatment Diversity Takashi Ishikawa(Tokyo Medical Univ., Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 11:05~11:20 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Closing the Gap in Radiotherapy Access in Asia Mei Ling Yap(Univ. of New South Wales, Australia)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 11:20~11:35 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Age and National Disparities in the Decision-Making Process of Breast Cancer Patients Hee Jeong Kim(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 2 (Grand 1) 11:35~11:45 [Special Session: Policy on Breast Cancer: Bridging the Gap Between Guidelines and Real-World Practice] Discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 10:30~10:55 [Education Session 4: Less is More in Breast Cancer: Radiation Oncologists Timothy Whelan(McMaster Univ., Canada)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 10:55~11:20 [Education Session 4: Less is More in Breast Cancer: Radiation Oncologists Jeanny Kwon(Chungnam National Univ. Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 11:20~11:45 [Education Session 4: Less is More in Breast Cancer: Radiation Oncologists Isabelle Kindts(AZ Groeninge, Belgium)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 10:30~10:55 [Nursing Session 2: Managements of Hair Loss and Skin Change for Breast Cancer Patients] Management of Skin Changes in Breast Cancer Patients Kyungmin Na(Daerim St. Mary)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 10:55~11:20 [Nursing Session 2: Managements of Hair Loss and Skin Change for Breast Cancer Patients] Effectiveness of Cooling Cap to Prevent Persistent Chemotherapy-Induced Alopecia Among Patients with Breast Cancer: A Randomized Controlled Trial Juhee Cho(SAIHST, Sungkyunkwan Univ., Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 11:20~11:45 [Nursing Session 2: Managements of Hair Loss and Skin Change for Breast Cancer Patients] Experience of Scalp Cooling Among Breast Cancer Nayeon Kim(Samsung Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 10:30~10:55 [Session on Digital Health: The New Era of Digital Leading Innovation in Healthcare] Tech & Patient-Centric Cancer Care Eunsu Park(Lunit Care, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 10:55~11:20 [Session on Digital Health: The New Era of Digital Leading Innovation in Healthcare] HRS: Standard-Based Multi-Institutional Research Platform Soo-Yong Shin(Kakao Healthcare, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 6 (Grand 4) 11:20~11:45 [Session on Digital Health: The New Era of Digital Leading Innovation in Healthcare] Digital Healthcare 2024: Age of Generative AI Koon-Ho Rha(Naver Healthcare, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 11:45~12:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 12:00~12:45 [Plenary Lecture 3] Lobular Carcinoma - Current Concepts and Controversies Tari King(Dana-Farber Brigham Cancer Center, U.S.A.)

ÈÞ½Ä 04¿ù 26ÀÏ 12:45~13:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 13:00~13:45 [Satellite Symposium 3: MSD Korea] The Promising Role of Pembrolizumab in Transforming the Landscape for eTNBC Jin Seok Ahn(Samsung Medical Center, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 13:45~14:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 14:00~14:45 [Plenary Lecture 4] Origins, Evolution, and Clinical Implications of the Integrative Breast Cancer Subtypes Christina Curtis(Stanford Univ., U.S.A.)

ÈÞ½Ä 04¿ù 26ÀÏ 14:45~15:00 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 15:00~15:25 [Symposium 7: Neoantigen-Based Personalized Therapy] Neoantigen Analysis Sangwoo Kim(Yonsei Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 15:25~15:50 [Symposium 7: Neoantigen-Based Personalized Therapy] Neoantigen-Targeted Vaccine Soonmyung Paik(Theragen Bio, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 15:50~16:15 [Symposium 7: Neoantigen-Based Personalized Therapy] Neoantigen-Targeted Cell Therapy Hee Jin Lee(ASAN Medical Center, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 15:00~15:20 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Breast Conserving Surgery in Breast Cancer with BRCA1/2 Mutation Carriers Tristen Park(Yale School of Medicine, U.S.A.)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 15:20~15:40 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Is All Unilateral Breast Cancer with BRCA1/2 Mutation Carriers Recommended Contralateral Risk Reducing Mastectomy? Isabel T. Rubio(Clinica Universidad de Navarra, Spain)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 15:40~16:00 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Risk Reducing Mastectomy Beyond BRCA1/2 Mutation Carriers Sung-Won Kim(Daerim St. Mary)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:00~16:15 [Panel Discussion 6: Surgical Management for Individuals with Germline Mutation Carriers] Discussion ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 15:00~15:25 [Education Session 5: Toxicity of Novel Agents: A Call for Attention] Antibody Drug Conjugates Janice Tsang(The Univ. of Hong Kong, Hong Kong )

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 15:25~15:50 [Education Session 5: Toxicity of Novel Agents: A Call for Attention] Targeted Therapeutics in Hormone Positive Breast Cancers Yoon-Sim Yap(National Cancer Centre Singapore, Singapore)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 15:50~16:15 [Education Session 5: Toxicity of Novel Agents: A Call for Attention] Immunotherapies: Short and Long Term Kyoung Eun Lee(Ewha Womans Univ. Mokdong Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 15:00~15:20 [Session on OPBS] The Future of Oncoplastic Surgery: Innovations and Challenges in the Age of Personalized Breast Cancer Surgery Mee-Hoong See(Faculty of Medicine, Univ. Malaya, Malaysia)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 15:20~15:40 [Session on OPBS] Oncoplastic Surgery in the Modern Era: Balancing Surgical Outcomes with Patient Satisfaction Jeeyeon Lee(Kyungpook National Univ. Chilgok Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 15:40~16:00 [Session on OPBS] Considerations for Immediate Breast Reconstruction in Patients at High Risk of Radiation Therapy Tomoyuki Yano(Cancer Institute Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 16:00~16:15 [Session on OPBS] Surgical Difficulty of Nipple-Sparing Mastectomy and Reconstruction Based on Mastectomy Incision Location Hyun Ho Han(ASAN Medical Center, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 15:00~15:40 [GBCC-CACA Joint Session: The Strategy of HER-2 Positive Breast Cancer or New Drugs of Metastatic Breast Cancer] Advancements in Targeted Therapies: Managing HER2+ Metastatic Breast Cancer in Chinese Patients Pengfei Qiu(Shandong Cancer Hospital and Institute, China)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 15:40~16:15 [GBCC-CACA Joint Session: The Strategy of HER-2 Positive Breast Cancer or New Drugs of Metastatic Breast Cancer] Exploring Emerging Strategies: Addressing Triple-Negative Metastatic Breast Cancer in Korean Patients Koung Jin Suh(Seoul National Univ. Bundang Hospital, Korea)

ÈÞ½Ä 04¿ù 26ÀÏ 16:15~16:30 Break ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 16:30~16:55 [Symposium 8: Antibody Drug Conjugates: Reshaping the Landscape of Breast Cancer Treatment] Antibody-Drug Conjugates: The Evolution of Development and Current Landscape in Breast Cancer Kyong Hwa Park(Korea Univ. Anam Hospital, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 16:55~17:20 [Symposium 8: Antibody Drug Conjugates: Reshaping the Landscape of Breast Cancer Treatment] Unresolved Problem in Real-World Practice: Toxicities and Management of Brain Metastases Chun-Yu Liu(National Yang Ming Chiao Tung University, Taiwan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 1 (Vista 1+2) 17:20~17:45 [Symposium 8: Antibody Drug Conjugates: Reshaping the Landscape of Breast Cancer Treatment] Future Directions: Resistance Mechanism of ADCs and Strategies to Overcome Sarat Chandarlapaty(Memorial Sloan Kettering Cancer Center, U.S.A.)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:30~16:37 [Special Session: Debate Session] Do we Really Need to Use Neoadjuvant IO in ER+, eBC? Jee Hung Kim(Gangnam Severance Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:37~16:44 [Special Session: Debate Session] Do we Really Need to Use Neoadjuvant IO in ER+, eBC? Dae-Won Lee(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 16:44~17:04 [Special Session: Debate Session] Discussion 1 ()

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 17:04~17:11 [Special Session: Debate Session] What Is the Role of Adjuvant IO After Achieving pCR in eTNBC Following Neoadjuvant IO Treatment? Jee Hung Kim(Gangnam Severance Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 17:11~17:18 [Special Session: Debate Session] What Is the Role of Adjuvant IO After Achieving pCR in eTNBC Following Neoadjuvant IO Treatment? Dae-Won Lee(Seoul National Univ. Hospital, Korea)

Åä·Ð 04¿ù 26ÀÏ Room 2 (Grand 1) 17:18~17:45 [Special Session: Debate Session] Discussion 2 ()

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 16:30~16:55 [Education Session 6: Estrogen, Obesity, and Sarcopenia: Biology and Life Style] Overview Estrogen Pathway and Association with Obesity in Breast Cancer Jennifer Ligibel(Dana-Farber Cancer Institute, U.S.A.)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 16:55~17:20 [Education Session 6: Estrogen, Obesity, and Sarcopenia: Biology and Life Style] Effect of Adjuvant Treatment on Obesity, Sarcopenia in Breast Cancer Patients Young-Jin Suh(The Catholic Univ. of Korea, St. Vincent)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 3 (Walker Hall 1) 17:20~17:45 [Education Session 6: Estrogen, Obesity, and Sarcopenia: Biology and Life Style] The Role of Obesity and Sarcopenia in Anti-Cancer Immunotherapy Yen-Shen Lu(National Taiwan Univ. Hospital, Taiwan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 16:30~16:55 [Session on HBOC] Long-Term Outcome of BRCA1/2 Mutation with Breast Cancer in Asia Ava Kwong(The Univ. of Hong Kong, Hong Kong )

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 16:55~17:20 [Session on HBOC] Is It Time BRCA1/2 Genetic Test as a Companion Diagnosis of Breast Cancer? Seigo Nakamura(Showa Univ. School of Medicine, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 4 (Walker Hall 2) 17:20~17:45 [Session on HBOC] Gastric Cancer Risk and Management in BRCA1/2 Mutation Yoon Young Choi(Soonchunhyang Univ. Hospital Bucheon, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 16:30~16:50 [GBCC-JBCS Joint Session] De-Escalation Therapy for Low-Risk HER2-Positive Early-Stage Breast Cancer Kazuki Nozawa(Aichi Cancer Center Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 16:50~17:10 [GBCC-JBCS Joint Session] Prognostic Impact of Adjuvant Endocrine Therapy by Age for Patients with T1a/bN0M0 ER-Positive and HER2-Negative Breast Cancer Yuko Takahashi(Okayama Univ. Hospital, Japan)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 17:10~17:30 [GBCC-JBCS Joint Session] Cohort Study of Asian Breast Cancer Patients with BRCA 1/2 Mutation (KoREa-BSG 06) Chihwan Cha(Hanyang Univ. College of Medicine, Korea)

±³À°½Ã°£ 04¿ù 26ÀÏ Room 5 (Art Hall) 17:30~17:45 [GBCC-JBCS Joint Session] Prospective Single-Arm Study of Endocrine Therapies with Ovarian Function Suppression in Premenopausal Node-Positive Early Breast Cancer Patients with Low Genomic Risk (INTERSTELLAR Trial, KBCSG-25) Sung Gwe Ahn(Gangnam Severance Hospital, Korea)

 

  • ÃßõÇϱâ
Tip. ±³À°ÀÏÁ¤Àº ±³À°±â°üÀÇ »çÁ¤¿¡ µû¶ó º¯°æµÉ ¼ö ÀÖÀ¸¹Ç·Î »çÀü¿¡ ¹Ýµå½Ã ±³À°±â°üÀ¸·Î ¹®ÀÇÇÏ¿© È®ÀÎ ¹Ù¶ø´Ï´Ù.
¡å
ÀÛ¼ºÀÚ   ºñ¹Ð¹øÈ£
 
¿¬¼ö°­Á ÁÖ°£º£½ºÆ®
Á¦¸ñ

[¼­¿ï] ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ : 2018-11-04

±³À°ÀÏÀÚ : 2018-11-04 ±³À°Àå¼Ò : ±×·£µåÈúÆ°È£ÅÚ(È«Àºµ¿) ÄÁº¥¼Ç¼¾ÅÍ ¿Ü ±³À°ÁÖÁ¦ : ´ëÇÑÇǺΰúÀÇ»çȸ ⸳ 20Áֳ⠱â³äÇà»ç ¹× Á¦21ȸ Ãß°èÇмú´ëȸ ÁÖÃÖ±â°ü : ´ëÇÑ

Ãßõ¼ö : 0 , Á¶È¸¼ö : 11,028 , ´ñ±Û¼ö : 0

[¼­¿ï] (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­Á : 2024-03-30

±³À°ÀÏÀÚ : 2024-03-30 ±³À°Àå¼Ò : ¿Â¶óÀÎ »ýÁß°è ±³À°ÁÖÁ¦ : (¿Â¶óÀÎ)Á¦27Â÷ ´ç´¢º´ ±³À°ÀÚ ¿¬¼ö°­ÁÂÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ ´ã´çÀÚ : °û¼ÖÀÌ ¿¬¶ôó : 02-71

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,817 , ´ñ±Û¼ö : 0

[¼­¿ï] ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä) : 2024-02-25

±³À°ÀÏÀÚ : 2024-02-25 ±³À°Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø º»°ü ÁöÇÏ 1Ãþ ±èÁ¾±â Ȧ ±³À°ÁÖÁ¦ : ¼­¿ï´ëÇб³º´¿ø »êºÎÀΰú ¿¬¼ö°­Á (ÀüÁ¾°ü ±³¼ö´Ô ¸í¿¹ÅðÀÓ ±â³ä)ÁÖÃÖ±â°ü : ¼­

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,895 , ´ñ±Û¼ö : 0

[´ë±¸] 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2023-04-20

±³À°ÀÏÀÚ : 2023-04-20 ±³À°Àå¼Ò : È£ÅÚ ÀÎÅÍºÒ°í ´ë±¸ ÄÁº¥¼ÇȦAB ¿Ü ±³À°ÁÖÁ¦ : 2023³â Á¦74Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ ´ã

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,976 , ´ñ±Û¼ö : 0

[±¤ÁÖ] ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd day : 2024-04-26

±³À°ÀÏÀÚ : 2024-04-26 ±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁß ÄÁº¥¼Ç ¼¾ÅÍ ÄÁº£¼Ç Ȧ ¿Ü 8°÷ ±³À°ÁÖÁ¦ : ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦42Â÷ Ãá°èÇмú´ëȸ_2nd dayÁÖÃÖ±â°ü : ´ëÇѽŰæ¿Ü°ú

Ãßõ¼ö : 0 , Á¶È¸¼ö : 2,520 , ´ñ±Û¼ö : 0